Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Colin Pharmaceutical: Subsidiary SKB103 New Drug Clinical Trial Application Approved by the National Medical Products Administration
Kelun Pharmaceutical Announcement: The new drug clinical trial application for SKB103, a bispecific antibody-drug conjugate independently developed by its holding subsidiary Kelun Botai, has been approved by the National Medical Products Administration for the treatment of advanced solid tumors. This is Kelun Botai’s first TAA-PD-L1 bsADC to enter the clinical stage, and the second bsADC for tumor treatment to enter the clinical phase after SKB571.